IQVIA Holdings Inc. $IQV Shares Sold by First American Trust FSB

First American Trust FSB decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 88.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,918 shares of the medical research company’s stock after selling 30,024 shares during the quarter. First American Trust FSB’s holdings in IQVIA were worth $617,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of IQV. Brighton Jones LLC increased its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in shares of IQVIA by 7.5% during the 1st quarter. Mutual of America Capital Management LLC now owns 34,435 shares of the medical research company’s stock valued at $6,071,000 after buying an additional 2,405 shares during the period. Wealthfront Advisers LLC increased its holdings in shares of IQVIA by 7.4% during the 1st quarter. Wealthfront Advisers LLC now owns 4,310 shares of the medical research company’s stock worth $760,000 after buying an additional 296 shares during the last quarter. Larson Financial Group LLC boosted its holdings in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 144 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after acquiring an additional 566 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 2.0%

NYSE:IQV opened at $216.24 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market capitalization of $36.82 billion, a price-to-earnings ratio of 29.66, a price-to-earnings-growth ratio of 2.48 and a beta of 1.34. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12. The stock has a 50-day simple moving average of $203.29 and a 200 day simple moving average of $179.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter last year, the business posted $2.84 EPS. IQVIA’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. Redburn Partners set a $214.00 price objective on IQVIA in a report on Wednesday, September 3rd. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. JPMorgan Chase & Co. boosted their price objective on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Evercore ISI raised their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. Finally, Truist Financial reaffirmed a “buy” rating and set a $265.00 price target (up from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $241.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.